Weekly Research Analysts’ Ratings Updates for Rhythm Pharmaceuticals (RYTM)

Rhythm Pharmaceuticals (NASDAQ: RYTM) has recently received a number of price target changes and ratings updates:

• 1/20/2026 – Rhythm Pharmaceuticals had its price target raised by analysts at HC Wainwright from $123.00 to $125.00. They now have a “buy” rating on the stock.
• 1/20/2026 – Rhythm Pharmaceuticals had its price target raised by analysts at Wells Fargo & Company from $129.00 to $145.00. They now have an “overweight” rating on the stock.
• 1/19/2026 – Rhythm Pharmaceuticals was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating.
• 1/9/2026 – Rhythm Pharmaceuticals had its price target raised by analysts at Needham & Company LLC from $145.00 to $148.00. They now have a “buy” rating on the stock.
• 12/22/2025 – Rhythm Pharmaceuticals had its price target raised by analysts at HC Wainwright from $110.00 to $123.00. They now have a “buy” rating on the stock.
• 12/17/2025 – Rhythm Pharmaceuticals had its price target raised by analysts at Guggenheim from $120.00 to $140.00. They now have a “buy” rating on the stock.
• 12/17/2025 – Rhythm Pharmaceuticals had its “buy” rating reaffirmed by analysts at UBS Group AG.
• 12/12/2025 – Rhythm Pharmaceuticals had its price target raised by analysts at The Goldman Sachs Group, Inc. from $141.00 to $157.00. They now have a “buy” rating on the stock.
• 12/12/2025 – Rhythm Pharmaceuticals had its price target raised by analysts at Canaccord Genuity Group Inc. from $114.00 to $141.00. They now have a “buy” rating on the stock.
• 12/12/2025 – Rhythm Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Citigroup Inc..
• 12/12/2025 – Rhythm Pharmaceuticals had its price target raised by analysts at Citizens Jmp from $141.00 to $167.00. They now have a “market outperform” rating on the stock.
• 12/11/2025 – Rhythm Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $150.00 price target on the stock.
• 12/11/2025 – Rhythm Pharmaceuticals had its “buy” rating reaffirmed by analysts at Cowen Inc.
• 12/11/2025 – Rhythm Pharmaceuticals had its price target raised by analysts at Needham & Company LLC from $120.00 to $145.00. They now have a “buy” rating on the stock.
• 11/25/2025 – Rhythm Pharmaceuticals is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $136.00 price target on the stock.
• 11/25/2025 – Rhythm Pharmaceuticals is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $136.00 price target on the stock.

Insider Buying and Selling

In related news, insider Pamela J. Cramer sold 3,350 shares of the company’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $111.00, for a total transaction of $371,850.00. Following the completion of the sale, the insider directly owned 20,814 shares in the company, valued at $2,310,354. This represents a 13.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Joseph Shulman sold 9,748 shares of Rhythm Pharmaceuticals stock in a transaction on Thursday, October 30th. The shares were sold at an average price of $115.24, for a total transaction of $1,123,359.52. Following the completion of the sale, the insider owned 8,509 shares in the company, valued at approximately $980,577.16. This trade represents a 53.39% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 15,913 shares of company stock worth $1,818,963 over the last ninety days. Insiders own 6.10% of the company’s stock.

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.